Company Focus
Chugai
Latest Chugai News
Biotechnology
National Health Service (NHS) England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with moderate hemophilia A with a severe bleeding phenotype who do not have factor VIII inhibitors. 2 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Chugai
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 clinical trial (also known as KEYNOTE-905). 12 August 2025
Generics
US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients aged two years of age and older, with chronic kidney disease (CKD). 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Latest In Brief for Chugai
Biotechnology
US biotech Genascence today announced the US Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). 16 July 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze